The global depression therapeutics market is expected to grow at a significant CAGR during the forecast period (2021-2027). The rise in the geriatric population and changes in people’s lifestyles are two primary factors driving the market growth. The ageing population is anticipated to grow continuously, at a uniform rate in the next 10 years. For instance, according to the World Health Organization (WHO), the number of people aged 60 years or above was around 900 million in 2015 and it is estimated to reach nearly 2.0 billion in 2050, with most of the increase in the developing countries. In 2019, in Japan, people aged 65 years or above held 28% of the total country’s population (126 million) and followed by it, Italy held 23%. Depression is one of the major conditions amongst older people having a significant effect on their well-being and quality of life.
To Request a Sample of our Report on Global Depression Therapeutics Market: https://www.omrglobal.com/request-sample/depression-therapeutics-market
People are being made aware of depression through public awareness campaigns. Although public awareness is growing, this ailment is still underdiagnosed and undertreated. The patient is treated with a combination of psychotherapy and antidepressants. Selective serotonin reuptake inhibitors are predicted to lead the drug class segment during the forecast period owing to the high level of effectiveness and general safety. Additionally, North America depression therapeutics market is significantly driven by significant antidepressant consumption in the US, branded medications, and an active lifestyle. Moreover, Europe depression therapeutics market is driven by the rising public knowledge about depression and improved healthcare facilities and initiatives by various government and non-government organisations.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Pfizer, Inc., Eli Lilly Co., H. Lundbeck A/S, and Otsuka Holdings Co., Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Depression Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/depression-therapeutics-market
Global Depression Therapeutics Market Report by Segment
By Drug Type
• Antidepressants
• Antipsychotics
• Others
By Indication
• Major Depressive Disorder (MDD)
• Bipolar Disorder
• Seasonal Affective Disorder (SAD)
• Premenstrual Dysphoric Disorder (PMDD)
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Depression Therapeutics Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
